ProQR Therapeutics Stock (NASDAQ:PRQR), Trade Ideas

ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACST

AGFY

AKTS

ARAV

ATAK

CANO

CELU

CURO

CUTR

CVKD

DADA

EHTH

LANV

LICY

LUXH

LXEO

Airspan Networks Holdings Inc. Common Stock

MIMO

MMAT

MRAI

MRSN

NCAC

NUKK

NVVE

PCSA

PHUN

PLUG

PRQR

RAMP

ROMA

SAVE

SIFY

ZCAR

ZVSA

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results.

Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ABAT

ACIC

ACXP

ADAG

ALEC

BFRG

CART

CGTX

COMP

CRGE

CVGW

DOCN

DWAC

ESPR

FTEL

HOVR

Kintara Therapeutics, Inc. - Common Stock

KTRA

LQDA

MARK

MNSO

PRGS

RNAZ

RVSN

SBGI

SEDG

SHOT

TELL

TREE

Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module.

Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.

Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

BDRX

BGLC

IMPL

RDHL

SHOP

THAR

U.S. stocks traded lower this morning, with the Dow Jones index falling over 50 points on Monday.

Following the market opening Monday, the Dow traded down 0.18% to 35,328.05 while the NASDAQ fell 0.13% to 14,231.78. The S&amp;P 500 also fell, dropping, 0.25% to 4,548.14.

US Stocks Lower; Dow Falls Over 50 Points

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics NV

Biotech

Events

General

ProQR Therapeutics To Present On Axiomer RNA Editing At ASGCT 27th Annual Meeting

The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.
The opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR&#39;s granted patent&nbsp;<a href="https://www.globenewswire.com/Tracker?data=2Ct1VlHTN7s9kKLzuYjjceoprNCVAnRgUXOy9TbpbOkved0Wb0LKvKfwvcte2z9f0uiOJYBnah3BwVLHtWsFlh14ptX8M2hNCCt0TV84gUnQybAQSnfAzumrPTbCoa85TdnYF5Bje4KPY3O1eTz0OA==" target="_blank">EP 3 507 366 B1</a>,&nbsp;which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR&#39;s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules. The Opposition Division of the EPO held a public hearing on April 17, 2024, and ruled such that ProQR&#39;s strong IP position on chemically modified editing oligonucleotides was maintained.
The patent contains broad platform claims including: &quot;An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell&hellip;&quot;, which protects ProQR&#39;s proprietary ADAR mediated RNA editing platform Axiomer.
&quot;This decision further supports the confidence we have in the broad scope conferred by our IP estate protecting our proprietary Axiomer ADAR-mediated RNA editing technology platform, and the use of chemically modified oligonucleotides to increase stability and recruit endogenous ADAR to edit the target adenosine,&quot; said Ren&eacute; Beukema, Chief Corporate Development Officer and General Counsel. &quot;Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leading position, as we progress our science, platform, and pipeline.&quot;
ProQR invented the use of endogenous ADAR in RNA editing in 2014 and filed a first patent application in that same year.&nbsp;

ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and raises the price target from $2 to $2.5.

Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5

WIIM

ProQR Therapeutics shares are trading higher after the company reported a year-over-year increase in FY23 EPS results.

Guidance

Health Care

ProQR Therapeutics' 2023 Cash And Cash Equivalents Of €118.9M Is Expected To Provide Cash Runway Into Mid-2026

ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) reported quarterly losses of $(0.38) per share. This is a 61.09 percent increase over losses of $(0.97) per share from the same period last year.

ProQR Therapeutics FY EPS $(0.38) Up From $(0.97) YoY

Legal

ProQR Says Japanese Axiomer Patent Upheld Following Opposition Against Its IP Estate For ADAR-Mediated RNA Editing

ProQR Therapeutics Highlights New Platform Data From Presentation On Axiomer RNA Editing Technology, Company Says Platform Demonstrates Robust In Vivo Editing Capabilities Reporting Up To 70% Editing Of ACTB In Liver Of Non-human Primates (NHPS) And Mice

<ul>
<li>Platform demonstrates robust&nbsp;in vivo&nbsp;editing capabilities reporting up to&nbsp;70%&nbsp;editing of ACTB in the liver of non-human primates (NHPs) and mice</li>
<li>Functional effect demonstrated in mice&nbsp;in vivo&nbsp;via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkers</li>
<li>Additional data to be presented throughout 2024, including&nbsp;in vitro&nbsp;and&nbsp;in vivo&nbsp;data for pipeline programs AX-0810 for Cholestatic diseases targeting NTCP and AX-1412 for Cardiovascular diseases targeting B4GALT1</li>
</ul>

ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024

Shares of KeyCorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/key#NYSE">KEY</a>) moved lower during Thursday&rsquo;s session after the company reported fourth-quarter financial results.
Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.
KeyCorp shares fell 5.4% to $13.10 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyt#NASDAQ">LYT</a>) shares jumped 92.8% to $0.1824 after falling 5% on Wednesday.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) shares jumped 90% to $2.2401. Agrify said it entered into first Hydrocarbon Extraction Lab &amp; Vertical Farming unit facility in California.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) shares jumped 67.9% to $0.2730. Phunware shares dipped 61% on Wednesday after the company announced pricing of a $7 million registered direct offering price at-the-market under Nasdaq rules.</li>
<li>Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) shares surged 43.4% to $0.2705 after falling more than 5% on Wednesday.</li>
<li>Marpai, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrai#NASDAQ">MRAI</a>) shares jumped 34.4% to $1.1359 after declining over 8% on Wednesday. Marpai recently named John Powers as President.</li>
<li>Akoustis Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akts#NASDAQ">AKTS</a>) gained 21.7% to $0.7698.</li>
<li>Baijiayun Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rtc#NASDAQ">RTC</a>) gained 18.8% to $3.73.</li>
<li>M.D.C. Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdc#NYSE">MDC</a>) rose 18.2% to $62.76 after the company announced it will be acquired by Sekisui House.</li>
<li>CURO Group Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/curo#NYSE">CURO</a>) gained 15.7% to $0.8499.</li>
<li>Lexeo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxeo#NASDAQ">LXEO</a>) rose 13% to $19.58.</li>
<li>Aurora Technology Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atak#NASDAQ">ATAK</a>) gained 13% to $4.79.</li>
<li>Acasti Pharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acst#NASDAQ">ACST</a>) jumped 12.4% to $2.45.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) gained 11.8% to $1.6750. Dada Nexus recently announced that it discovered suspicious practices in an internal audit.</li>
<li>Cadrenal Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvkd#NASDAQ">CVKD</a>) surged 11.8% to $0.9499 after gaining over 7% on Wednesday.</li>
<li>Lanvin Group Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lanv#NYSE">LANV</a>) jumped 9.3% to $2.5901.</li>
<li>LiveRamp Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ramp#NYSE">RAMP</a>) gained 9.2% to $40.30. LiveRamp Holdings said it sees preliminary third-quarter revenue of $174 million and announced plans to acquire Habu.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) surged 8.8% to $1.24 after tumbling over 70% on Wednesday.</li>
<li>Taiwan Semiconductor Manufacturing Company Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) gained 8.1% to $111.26 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htz#NASDAQ">HTZ</a>) gained 7.1% to $8.95 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight but cut its price target form $16 to $15.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aravive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arav#NASDAQ">ARAV</a>) shares dipped 50.9% to $0.0542. Aravive intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) fell 28.7% to $0.1975. Processa Pharmaceuticals said it will effect a 1-for-20 reverse stock split.</li>
<li>Newcourt Acquisition Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncac#NASDAQ">NCAC</a>) shares fell 27.3% to $8.43 after gaining around 12% on Wednesday.</li>
<li>Cano Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cano#NYSE">CANO</a>) dipped 26.4% to $1.76.</li>
<li>eHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ehth#NASDAQ">EHTH</a>) fell 23.3% to $5.36. Craig-Hallum analyst George Sutton downgraded eHealth from Buy to Hold.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) declined 23% to $0.53. ZyVersa Therapeutics recently announced the publication of an article in the peer-reviewed journal Acta Neuropathologica Communications, demonstrating that inflammasome activation enhances cancer metastasis to the brain in women with triple-negative breast cancer (TNBC).</li>
<li>ProQR Therapeutics N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prqr#NASDAQ">PRQR</a>) fell 20.4% to $2.2678.</li>
<li>Li-Cycle Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/licy#NYSE">LICY</a>) declined 18.5% to $0.4251.</li>
<li>LuxUrban Hotels Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/luxh#NASDAQ">LUXH</a>) fell 18% to $3.5430. LuxUrban responded to allegations in short seller report, highlighting mischaracterizations and speculation.</li>
<li>Nuvve Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvve#NASDAQ">NVVE</a>) shares fell 18.2% to $0.0830. Nuvve Holding will effect 1-for-40 reverse stock split, to be effective Jan. 19, 2024.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcar#NASDAQ">ZCAR</a>) fell 16.8% to $4.25. Zoomcar recently appointed Adarsh Menon as President.</li>
<li>QuantaSing Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) declined 16.4% to $2.5410. QuantaSing said it launched private label Chinese Baijiu brand YUNTING.</li>
<li>Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) fell 16% to $3.0601. Cutera recently reported preliminary FY23 revenue guidance above prior estimates.</li>
<li>Airspan Networks Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mimo#NASDAQ">MIMO</a>) shares declined 13.5% to $0.1900. Airspan shares jumped 186% on Wednesday after the company announced a partnership with GCT Semiconductor to develop an RF module.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) fell 12.2% to $5.39 on continued downward momentum after a federal judge blocked JetBlue Airways from acquiring the company. Citigroup analyst Stephen Trent downgraded Spirit Airlines from Neutral to Sell and lowered the price target from $13 to $4.</li>
<li>Plug Power Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plug#NASDAQ">PLUG</a>) shares dipped 12.1% to $2.4050 after the company announced it entered into an at market issuance sales agreement with B. Riley Securities for a common stock offering of up to $1 billion.</li>
<li>Meta Materials Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmat#NASDAQ">MMAT</a>) shares declined 11.8% to $0.0673 after gaining 5% on Wednesday.</li>
<li>Humana Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) fell 11.5% to $396.49 after the company issued soft 2023 adjusted EPS guidance.</li>
<li>Fortuna Silver Mines Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsm#NYSE">FSM</a>) declined 11.2% to $3.14. Fortuna Silver Mines said fourth-quarter gold equivalent production rose 6% sequentially, while silver production fell 19% quarter-over-quarter.</li>
<li>Sify Technologies Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sify#NASDAQ">SIFY</a>) dipped 10.8% to $1.56 after the company reported worse-than-expected third-quarter sales results.</li>
<li>Nukkleus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nukk#NASDAQ">NUKK</a>) fell 9.4% to $1.2510 after falling 6% on Wednesday. Nukkleus announced its intention to expand its investment in Jacobi Asset Management, known for sponsoring Europe&rsquo;s first approved Bitcoin spot ETF.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) dipped 8.3% to $2.65.</li>
<li>Discover Financial Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dfs#NYSE">DFS</a>) fell 6.9% to $101.22 after the company reported a 62% plunge in its profit for the fourth quarter on Wednesday.</li>
<li>U.S. Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>) slipped 3.7% to $39.31.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36673023/jim-cramer-says-buy-this-utilities-stock-down-6-over-past-6-months-calls-bunge-a-battleg"> Jim Cramer Says Buy This Utilities Stock Down 6% Over Past 6 Months, Calls Bunge A &#39;Battleground&#39;</a>

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of Airspan Networks Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mimo#NASDAQ">MIMO</a>) shares rose sharply during Wednesday&rsquo;s session after the company announced a partnership with GCT Semiconductor to develop an RF module.
Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) gained 31% to $0.1144.</li>
<li>LQR House Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqr#NASDAQ">LQR</a>) gained 30.4% to $2.6344 after dipping 45% on Tuesday. LQR House announced an increase of its share buyback program to $5 million.</li>
<li>ProQR Therapeutics N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prqr#NASDAQ">PRQR</a>) rose 29% to $3.2123.</li>
<li>Safety Shot, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shot#NASDAQ">SHOT</a>) climbed 26.7% to $2.2692. Safety Shot responded to FSD Pharma&#39;s unauthorized tagging of its stock and making false claims in an effort to harm the company and its shareholders.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) gained 27% to $3.3626 after the company reported early results from its collaboration with Lieber Institute for Brain Development (LIBD).</li>
<li>Fitell Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftel#NASDAQ">FTEL</a>) rose 25.7% to $1.2451.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares climbed 25.6% to $0.1594 after falling more than 9% on Tuesday.</li>
<li>Cognition Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgtx#NASDAQ">CGTX</a>) gained 22.4% to $2.5339.</li>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) rose 22% to $2.0510 as the company said that a leading US-based rail and leasing services company signed a supply contract with Rail Vision valued at up to $5,000,000 for the purchase of Rail Vision&rsquo;s AI-based Switch Yard Systems.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) jumped 17.5% to $26.25 after Donald Trump recently won the Iowa GOP caucus. Digital World Acquisition Corp is the business combination partner of Trump Media &amp; Technology Group.</li>
<li>American Coastal Insurance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acic#NASDAQ">ACIC</a>) gained 17.1% to $11.58 after Raymond James initiated coverage on the stock with an Outperform rating and announced a $15 price target.</li>
<li>Sinclair, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbgi#NASDAQ">SBGI</a>) gained 13.6% to $15.47. Sinclair reached a preliminary agreement to settle the lawsuit filed by Diamond Sports Group, LLC (DSG) and its subsidiary Diamond Sports Net, LLC in July 2023.</li>
<li>Impinj, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pi#NASDAQ">PI</a>) surged 10.6% to $90.50 after the company reported preliminary revenue and adjusted EBITDA for the fourth quarter.</li>
<li>Liquidia Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) gained 10.4% to $13.67.</li>
<li>Maplebear Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cart#NASDAQ">CART</a>) gained 8.4% to $25.90 after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a $35 price target.</li>
<li>Progress Software Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prgs#NASDAQ">PRGS</a>) rose 3.4% to $55.41 as the company posted stronger-than-expected results for its fourth quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>TuSimple Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsp#NASDAQ">TSP</a>) shares tumbled 54.7% to $0.3201 after the company announced its intention to delist from Nasdaq.</li>
<li>Phunware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/phun#NASDAQ">PHUN</a>) fell 50% to $0.2099 after the company announced pricing of a $7 million registered direct offering price at-the-market under Nasdaq rules.</li>
<li>Adagene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adag#NASDAQ">ADAG</a>) declined 46.5% to $2.03 after the company announced the presentation of ADG126 data.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) fell 32.6% to $2.5650.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) declined 31.5% to $2.68.</li>
<li>Remark Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mark#NASDAQ">MARK</a>) fell 27.7% to $0.4899.</li>
<li>Acurx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acxp#NASDAQ">ACXP</a>) fell 25.7% to $3.48. Acurx Pharmaceuticals released comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from its completed Phase 2b trial in patients with Clostridioides difficile Infection (CDI).</li>
<li>American Battery Technology Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abat#NASDAQ">ABAT</a>) fell 25% to $2.45</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) shares dipped 24.1% to $6.01 on continued downward momentum after a federal judge blocked JetBlue Airways from acquiring the company.</li>
<li>New Horizon Aircraft Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hovr#NASDAQ">HOVR</a>) fell 22.6% to $2.60.</li>
<li>Charge Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crge#NASDAQ">CRGE</a>) fell 22.2% to $0.1260</li>
<li>Calavo Growers, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvgw#NASDAQ">CVGW</a>) fell 15.4% to $24.56. Calavo Growers delayed release of its fourth-quarter and FY23 financial results.</li>
<li>Alector, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alec#NASDAQ">ALEC</a>) declined 14.4% to $6.54 after the company announced the pricing of a $75 million public offering of 10,869,566 shares of common stock.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) fell 11.8% to $0.8519. TD Cowen analyst Jeffrey Osborne downgraded Fisker from Outperform to Market Perform and lowered the price target from $11 to $1.</li>
<li>Richtech Robotics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rr#NASDAQ">RR</a>) fell 11.7% to $6.59.</li>
<li>LendingTree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tree#NASDAQ">TREE</a>) shares tumbled 10.5% to $25.39.</li>
<li>Nukkleus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nukk#NASDAQ">NUKK</a>) fell 9.3% to $1.36. Nukkleus signed MOU to increase holdings in Jacobi Asset Management.</li>
<li>Compass, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/comp#NYSE">COMP</a>) declined 8.8% to $2.9350.</li>
<li>Tellurian Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tell#NYSE">TELL</a>) fell 8.6% to $0.6126.</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axl#NYSE">AXL</a>) fell 8.1% to $7.34 after UBS downgraded the stock from Neutral to Sell and lowered its price target from $8 to $6.5.</li>
<li>Definitive Healthcare Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dh#NASDAQ">DH</a>) tumbled 8.1% to $8.45. Definitive Healthcare named Jason Krantz as Interim CEO, succeeding Robert Musslewhite.</li>
<li>10x Genomics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txg#NASDAQ">TXG</a>) fell 7.8% to $41.04.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) dipped 6.9% to $2.6150.</li>
<li>HDFC Bank Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hdb#NYSE">HDB</a>) fell 6.8% to $56.99.</li>
<li>MINISO Group Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnso#NASDAQ">MNSO</a>) fell 6.8% to $21.00. MINISO shifted fiscal year end to Dec. 31 from June 30 for enhanced financial alignment.</li>
<li>DigitalOcean Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docn#NYSE">DOCN</a>) declined 5.8% to $32.94. DigitalOcean named Paddy Srinivasan as Chief Executive Officer.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sedg#NASDAQ">SEDG</a>) fell 5.7% to $68.63 after Barclays downgraded the stock from Equal-Weight to Underweight and lowered its price target from $74 to $50.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36653800/jim-cramer-says-hold-onto-this-biotech-stock-i-dont-understand-why-its-so-inexpensive"> Jim Cramer Says Hold Onto This Biotech Stock: &#39;I Don&#39;t Understand Why It&#39;s So Inexpensive&#39;</a>

Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

ProQR Therapeutics And Rett Syndrome Research Trust Join Forces With Axiomer RNA Editing Collaboration For Development Of Therapies For Central Nervous System Diseases

ProQR Therapeutics Divested Its Ophthalmic Assets, Sepofarsen And Ultevursen, To Laboratoires Théa For An Initial Payment Of €8M And May Be Eligible For Up To €165M In Milestone Payments

U.S. stocks traded lower this morning, with the Dow Jones index falling over 50 points on Monday.
Following the market opening Monday, the Dow traded down 0.18% to 35,328.05 while the NASDAQ fell 0.13% to 14,231.78. The S&amp;P 500 also fell, dropping, 0.25% to 4,548.14.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35955186/io-biotech-and-2-other-stocks-under-2-insiders-are-buying"> IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Communication services shares edged higher on Monday.
In trading on Monday, energy shares fell by 0.7%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Shopify Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shop#NYSE">SHOP</a>) merchants accomplished a record-breaking $4.1 billion in sales on Black Friday, marking a 22% <a href="https://www.benzinga.com/markets/equities/23/11/35953825/shopify-merchants-smash-records-with-black-friday-bonanza">increase from the previous year</a>.
Sales peaked when collective sales reached $4.2 million per minute at 12:01 p.m. EST.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
RedHill Biopharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdhl#NASDAQ">RDHL</a>) shares shot up 130% to $0.7241 after the company announced the FDA has granted five years&#39; market exclusivity for Talicia.
Shares of Biodexa Pharmaceuticals Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdrx#NASDAQ">BDRX</a>) got a boost, shooting 75% to $4.69 after the company announced it entered into agreements to acquire an exclusive worldwide license to tolimidone.
Tharimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thar#NASDAQ">THAR</a>) shares were also up, gaining 53% to $4.41 after the company reported Phase 1 data on TH104 for chronic pruritis in primary biliary cholangitis.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
BioNexus Gene Lab Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bglc#NASDAQ">BGLC</a>) shares dropped 21% to $0.71 after jumping 144% on Friday.
Shares of Impel Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/impl#NASDAQ">IMPL</a>) were down 14% to $0.73 after gaining 8% on Friday. Impel Pharmaceuticals recently announced exploration of strategic alternatives.
ProQR Therapeutics N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prqr#NASDAQ">PRQR</a>) was down, falling 18% to $1.21.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35955468/top-5-consumer-stocks-that-are-preparing-to-pump-this-quarter"> Top 5 Consumer Stocks That Are Preparing To Pump This Quarter</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.3% to $75.34 while gold traded up 0.5% at $2,012.40.
Silver traded up 2% to $24.82 on Monday while copper fell 0.8% to $3.7595.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.1%, London&rsquo;s FTSE 100 fell 0.2% while Spain&rsquo;s IBEX 35 Index rose 0.3% The German DAX fell 0.2% French CAC 40 slipped 0.1%, while Italy&rsquo;s FTSE MIB Index rose 0.1%.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Monday, with Japan&rsquo;s Nikkei 225 falling 0.53%, Hong Kong&rsquo;s Hang Seng Index falling 0.20% and China&rsquo;s Shanghai Composite Index falling 0.30%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell 0.1%.
Hong Kong&rsquo;s trade deficit increased to $25.8 billion in October from $20.9 billion in the year-ago month. Profits earned by Chinese industrial firms fell by 7.8% year-over-year to CNY 6,115.42 billion in the first ten months of 2023, compared to a 9.0 % decline in the previous period.
&nbsp;
<h3>Economics</h3>
&nbsp;
Data on new home sales will be released at 10:00 a.m. ET.
Now Read This: <a href="https://www.benzinga.com/news/23/11/35957603/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields</a>

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>
<ul>
<li>Piper Sandler cut Upstart Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upst#NASDAQ">UPST</a>) price target from $35 to $27. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Upstart shares fell 22.9% to $22.68 in pre-market trading. <a href="https://www.benzinga.com/quote/UPST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut the price target for NXP Semiconductors N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpi#NASDAQ">NXPI</a>) from $250 to $230. Needham analyst Quinn Bolton maintained a Buy rating. NXP Semiconductors shares fell 2.6% to $181.03 in pre-market trading. <a href="https://www.benzinga.com/quote/NXPI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stephens &amp; Co. slashed Noodles &amp; Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ndls#NASDAQ">NDLS</a>) price target from $5 to $4. Stephens &amp; Co. analyst Joshua Long maintained an Equal-Weight rating. Noodles shares closed at $2.20 on Tuesday. <a href="https://www.benzinga.com/quote/NDLS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital cut the price target for ContextLogic Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wish#NASDAQ">WISH</a>) from $6 to $4. Loop Capital analyst Laura Champine upgraded the stock from Sell to Hold. ContextLogic shares rose 1.4% to $4.28 in pre-market trading. <a href="https://www.benzinga.com/quote/WISH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group slashed the price target for Nextdoor Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kind#NYSE">KIND</a>) from $5 to $3. Evercore ISI Group analyst Mark Mahaney downgraded the stock from Outperform to In-Line. Nextdoor shares fell 2.2% to $1.78 in pre-market trading. <a href="https://www.benzinga.com/quote/KIND/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James increased Datadog, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>) price target from $95 to $115. Raymond James analyst Adam Tindle maintained an Outperform rating. Datadog shares fell 1.1% to $101.07 in pre-market trading. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James boosted bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) price target from $10 to $13. Raymond James analyst Dane Leone maintained an Outperform rating. bluebird bio shares gained 7.3% to close at $3.54 on Tuesday. <a href="https://www.benzinga.com/quote/BLUE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased the price target for Akamai Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akam#NASDAQ">AKAM</a>) from $120 to $134. Keybanc analyst Brandon Nispel maintained an Overweight rating. Akamai shares rose 0.4% to close at $108.86 on Tuesday. <a href="https://www.benzinga.com/quote/AKAM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James cut ProQR Therapeutics N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prqr#NASDAQ">PRQR</a>) price target from $5 to $4. Raymond James analyst Steven Seedhouse maintained an Outperform rating. ProQR Therapeutics shares gained 3.7% to $1.40 in pre-market trading. <a href="https://www.benzinga.com/quote/PRQR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised Squarespace, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sqsp#NYSE">SQSP</a>) price target from $38 to $40. Piper Sandler analyst Clarke Jeffries maintained an Overweight rating. Squarespace shares fell 1.4% to close at $29.65 on Tuesday. <a href="https://www.benzinga.com/quote/SQSP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/23/11/35667771/robinhood-ebay-upstart-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session"> Robinhood, eBay, Upstart And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session </a>

AKAM

BLUE

DDOG

KIND

NDLS

NXPI

SQSP

UPST

WISH

Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday

Raymond James analyst Steven Seedhouse maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Outperform and lowers the price target from $5 to $4.

Raymond James Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $4

Chardan Capital analyst Keay Nakae upgrades ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) from Neutral to Buy and announces $2 price target.

Upgrades

Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target

Citigroup analyst Yigal Nochomovitz maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and lowers the price target from $2.1 to $1.8.

Citigroup Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.8

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on… The biotech industry has seen considerable growth, propelled by significant strides in drug development, lucrative government support, and technology advancements. Therefore, investors could add fundamentally strong biotech stocks ProQR Therapeutics N.V. (<a href="https://stocknews.com/stock/PRQR/">PRQR</a>), Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), and Corcept Therapeutics Incorporated (<a href="https://stocknews.com/stock/CORT/">CORT</a>) to their portfolio now.
The biotech industry's growth prospects appear promising thanks to the heightened use of advanced technology, expansion in research pipelines, and <a href="https://www.biospace.com/article/2024-predictions-for-biotech-m-and-as-/">multibillion-dollar agreements</a>. These factors have collectively invigorated investor confidence in biotech stocks in recent months, as evidenced by the iShares Nasdaq Biotechnology Index Fund's (<a href="https://stocknews.com/stock/IBB/">IBB</a>) 18.8% return over the last three months.
Demand for drugs and vaccines is being driven up by a rise in chronic diseases and highly contagious diseases like <a href="https://www.newsnationnow.com/health/us-300-increase-measles/#:~:">measles</a>, thereby stimulating the biotech market. Furthermore, the industry has seen a significant investment funneled into medical <a href="https://www.businesswire.com/news/home/20240108742855/en/Biotech-companies-to-increase-RD-spend-but-highlight-complexity-of-clinical-trials---ICON">research and development</a>. The incorporation of advanced technologies is also enhancing the development of drugs, as well as progress in personalized medicine.
Innovative trends in bioprinting and tissue engineering have significantly fueled the biotech industry. The <a href="https://www.marketsandmarkets.com/Market-Reports/tissue-engineering-market-34135173.html#:">tissue engineering market</a>, reflecting robust growth, is forecasted to reach $8.90 billion by 2028, expanding at a CAGR of 15.3%.
Moreover, the industry is also experiencing burgeoning demand from agricultural applications such as tissue culturing, molecular breeding, and micro-propagation.
Furthermore, the "<a href="https://www.whitehouse.gov/wp-content/uploads/2023/03/Bold-Goals-for-U.S.-Biotechnology-and-Biomanufacturing-Harnessing-Research-and-Development-To-Further-Societal-Goals-FINAL.pdf">whole-of-government approach</a>" put forward by the Biden administration to advance biotechnology and biomanufacturing critically associated with health, climate change, energy, food security, agriculture, and supply chain resilience should keep the biotech industry buoyed in the foreseeable future.
Consequently, the <a href="https://www.precedenceresearch.com/biotechnology-market">global biotechnology market</a> is projected to reach $4.25 trillion, growing at a CAGR of 11.8% by 2033.
In light of these encouraging trends, let's look at the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with number 3.
Stock #3: ProQR Therapeutics N.V. (<a href="https://stocknews.com/stock/PRQR/">PRQR</a>)
Headquartered in Leiden, the Netherlands, PRQR discovers and develops novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide; and AX-1412 for cardiovascular diseases targeting Beta-1,4-galactosyltransferase 1. 
On January 5, PRQR collaborated with the Rett Syndrome Research Trust (RSRT) that will focus on the design and development of editing oligonucleotides using PRQR's Axiomer technology platform targeting the transcription factor Methyl CpG binding protein 2 and correcting mutations of interest.
RSRT awarded PRQR approximately $1 million as a research grant for the initial phase of the project, which will encompass editing oligonucleotide design and optimization, including evaluation in in-vivo models for editing efficacy and MECP2 protein recovery.
PRQR's trailing-12-month CAPEX/Sales of 15.23% is 273.5% higher than the industry average of 4.08%, while its trailing-12-month gross profit margin of 100% is 75.3% higher than the industry average of 57.05%.
For the fiscal third quarter that ended September 30, 2023, PRQR's revenue and cash and cash equivalents at the end of the period increased 68.3% and 20% year-over-year to €1.37 million ($1.49 million) and €120.55 million ($130.79 million), respectively.
As of September 30, 2023, PRQR's borrowings and <a href="https://www.investopedia.com/terms/a/accountspayable.asp">trade payables</a> stood at €2.34 million ($2.54 million) and €117 thousand ($126.94 thousand), compared to €2.50 million ($2.71 million) and €392 thousand ($425.30 thousand) as of December 31, 2022, respectively.
Street expects PRQR's revenue for the fiscal first quarter ending March 2024 to increase 293.6% year-over-year to $2.98 million. The company surpassed consensus EPS estimates in each of the trailing four quarters, which is impressive.
The stock has gained 55.2% over the past three months to close the last trading session at $2.10. Over the past six months, it has gained 35.2%.
PRQR's robust prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall B rating, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
The stock has an A grade for Growth and a B for Sentiment. It is ranked #24 within the 357-stock <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
<a href="https://stocknews.com/stock/PRQR/">Click here</a> for the additional POWR Ratings for PRQR (Value, Momentum, Stability, and Quality).
Stock #2: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. 
On February 16, REGN and Sanofi announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent – invented using Regeneron's proprietary VelocImmune&#xAE; technology – for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.
Japan became the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs. This should bode well for REGN.
On January 30, REGN announced the formation of Regeneron Cell Medicines based on the acquisition of full development and commercialization rights of 2seventy bio, Inc.'s pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities.
2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research &amp; development (R&amp;D) unit to advance cell therapies and combination approaches in oncology and immunology.
REGN's trailing-12-month cash per share of $25.49 is significantly higher than the industry average of $1.28. Also, its trailing-12-month levered FCF margin of 21.11% is significantly higher than the industry averages of 0.12%.
For the fiscal fourth quarter that ended December 31, 2023, REGN's revenues increased marginally year-over-year to $3.43 billion, while income from operations stood at $972.90 million. For the same quarter, its non-GAAP net income and non-GAAP net income per share stood at $1.37 billion and $11.86, respectively.
Moreover, for the fiscal year that ended December 31, 2023, its free cash flow stood at $3.88 billion.
Street expects REGN's revenue for the fiscal first quarter ending March 2024 to increase 1.7% year-over-year to $3.21 billion. Its EPS is expected to be $9.95 for the same quarter. The company surpassed consensus revenue and EPS estimates in each of the trailing four quarters.
The stock has gained 37% over the past nine months to close the last trading session at $993.35. Over the past year, it has gained 31.1%.
REGN's solid fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, translating to Buy in our proprietary rating system.
REGN has a B grade for Value and Quality. Within the same industry, it is ranked #14.
Beyond what we've stated above, we have also rated the stock for Growth, Momentum, Stability, and Sentiment. Get all ratings of REGN <a href="https://stocknews.com/stock/REGN/">here</a>.
Stock #1: Corcept Therapeutics Incorporated (<a href="https://stocknews.com/stock/CORT/">CORT</a>)
CORT discovers and develops drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the U.S. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. 
On January 8, CORT's Board of Directors approved a program authorizing the repurchase of up to $200 million of the company's common stock. The program does not require the company to repurchase any specific number of shares of its common stock.
CORT's trailing-12-month asset turnover ratio of 0.80x is 104.2% higher than the industry average of 0.39x, while its trailing-12-month levered FCF margin of 26.62% is significantly higher than the industry average of 0.12%.
For the fiscal fourth quarter that ended December 31, 2023, CORT's net product revenue and income from operations increased 31.4% and 40.8% year-over-year to $135.41 million and $31.67 million, respectively.
For the same quarter, its net income attributable to common stockholders and net income per common share stood at $31.14 million and $0.28, up 88.1% and 100% from the prior-year quarter, respectively.
Street expects CORT's revenue and EPS for the fiscal first quarter ending March 2024 to increase 33.3% and 61.4% year-over-year to $140.80 million and $0.23, respectively. The company surpassed consensus revenue estimates in each of the trailing four quarters and consensus EPS estimates in three of the trailing four quarters.
The stock has gained 15.3% over the past year to close the last trading session at $24.15. Over the past month, it has gained 11.5%.
CORT's POWR Ratings reflect its positive prospects. The stock has an overall A rating, equating to a Strong Buy in our proprietary rating system.
CORT has an A grade for Value and Quality and a B for Growth. Within the same industry, it is ranked #4.
To see additional POWR Ratings for Momentum, Stability, and Sentiment for CORT, <a href="https://stocknews.com/stock/CORT/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
REGN shares were unchanged in premarket trading Wednesday. Year-to-date, REGN has gained 13.10%, versus a 6.65% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Neha Panjwani</h2> <img src='https:/wp-content/uploads/2024/01/Neha-Panjwani_Headshot-1.jpeg' style="float:left; padding:5px;width:125px;">From her school days, Neha harbored a profound fascination for finance, a passion that steered her toward a career as an investment analyst following the completion of her bachelor's degree in commerce. Currently enrolled in the CFA program, Neha is dedicated to further enriching her comprehension of investment fundamentals.

Neha's primary objective is to aid retail investors in discerning optimal investment opportunities by diligently evaluating crucial aspects of financial instruments, with a primary focus on stocks and ETFs. Her commitment lies in empowering individuals to make informed and strategic investment decisions in the dynamic world of finance.<a href="https://stocknews.com/authors/?author=neha-panjwani">More...</a>The post <a href=https://stocknews.com/news/regn-cort-prqr-plunge-into-profits-with-these-3-biotech-stocks/>Plunge into Profits With These 3 Biotech Stocks</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Plunge into Profits With These 3 Biotech Stocks

Overall market sentiment has been high on ProQR Therapeutics NV (PRQR)  stock lately. PRQR receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. ProQR Therapeutics NV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PRQR!See Full PRQR ReportWhat is

Do Traders Think ProQR Therapeutics NV (PRQR) Can Keep Climbing Wednesday?

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProQR (PRQR – Research Report) and Crinetics Pharmac...

Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Crinetics Pharmaceuticals (CRNX)

In a report released yesterday, Keay Nakae from Chardan Capital maintained a Buy rating on ProQR (PRQR – Research Report), with a price target of $...

Buy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing Platform

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $5.0...

Buy Rating Affirmed: ProQR's Axiomer Platform Shows Promising Potential in CNS and Metabolic Disorders

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 3/15/2024, According to Top Analysts

ProQR Therapeutics BV (PRQR) has released an update. ProQR Therapeutics has announced the successful defense of their key Axiomer RNA editing platf...

ProQR Solidifies Lead in RNA Therapy Innovation

ProQR Therapeutics BV (PRQR) has released an update. ProQR Therapeutics has announced their upcoming Annual General Meeting for shareholders on May...

ProQR Therapeutics Announces Board Nomination and AGM

APLD

CORT

CRNX

RARE

REGN

Press Releases

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

ProQR Announces Third Quarter 2023 Operating and Financial Results

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing

ProQR Announces Year End 2023 Operating and Financial Results

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024